One-carbon Therapeutics to Present Trial-in-Progress Poster on ODIN Phase 1/2 Study ofTH9619 at the 2026 ASCO Annual Meeting
Solna, Sweden, May 29th, 2026. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies that exploit cancer’s oncogene addition, today announced that a Trial-in-Progress poster on its ongoing ODIN Phase 1/2 clinical study (NCT07151040) of TH9619 will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from […]
One-carbon Therapeutics Strengthens Board of Directors with Appointment of Stefan Larsson and Raj Shah
Solna, Sweden, May 21, 2026. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies, today announced the appointment of Stefan Larsson, MD, PhD, and Raj Shah, MD, as additional non-executive directors to its Board of Directors, effective April 28th. The appointments further strengthen scientific, operational and transactional expertise to the Board as the […]
One-carbon Therapeutics Announces Strategic Collaboration with Tempus to Advance Molecular Insights and Enable Precision Oncology Development of TH9619
Solna, Sweden, March 17h, 2026. One-carbon Therapeutics, a clinical-stage oncology company pioneering first-in-class targeted therapies based on deep understanding into cancer biology, today announced a strategic collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine. The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and […]
One-carbon Therapeutics announces oversubscribed private placement financing of SEK 153 million (€13.9 million)
Solna, Sweden, December 1, 2025. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies, announced today the closing of an oversubscribed 153 million SEK (€13.9 million) private placement financing round supported by current and new investors and private Swedish family offices. One-carbon Therapeutics will use the net proceeds from the private placement to […]
One-carbon Therapeutics AB Announces First Subject Dosed in the ODIN Phase 1/2 Clinical Study of TH9619 in Advanced Solid Tumors
Stockholm, Sweden. November 17th, 2025. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering a novel cancer therapy, today announced that the first subject has been successfully dosed in its ODIN Phase 1/2 clinical trial (NCT07151040) evaluating TH9619, a first-in-class MTHFD1/2 inhibitor. This milestone was achieved at START Madrid/Fundación Jiménez Díaz University Hospital, under the supervision of Dr. Victor Moreno, Director […]
One-carbon Therapeutics AB announces the addition of multiple international experts to its Scientific Advisory Board
Professor Johann de Bono, Head of the Division of Clinical Studies and Drug Development Unit and Experimental Cancer Medicine at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, UK. Professor Timothy Yap, Vice President and Head of Clinical Development in the Therapeutics Discovery Division, The Institute for Applied Cancer Science MD […]
We will be in Copenhagen for the NLS days 29-30 November
We look forward to meeting you there!
Trick or trap by One Carbon Therapeutics
Read a short story of One-carbon Therapeutics achievements so far in Nature Biopharma Dealmakers (https://www.nature.com/articles/d43747-023-00079-z). We are working hard to bring our novel inhibitor into the clinic.
We are selected as the EIT Health’s Catapult 2022-2023 runner-up finalist
We look forward to showcasing our innovative approach targeting difficult to treat cancers at the 2023 Bits & Pretzels Healthtech event in Munich 20-21 June.
We are presenting exciting progress about MTHFD1/2 inhibitors at BIO International in Boston
You can listen to our company presentation on Monday, June 5 and during the 12th International Cancer Cluster Showcase satellite symposium at BIO.